Prediction of venous thromboembolism in patients with cancer by measuring thrombin generation: Results from the vienna cancer and thrombosis study

Journal of Clinical Oncology

Volumn 29, Issue 15, 2011, Pages 2099-2103

  Ay, Cihan ^a   Dunkler, Daniela ^a   Simanek, Ralph ^a   Thaler, Johannes ^a   Koder, Silvia ^a   Marosi, Christine ^a   Zielinski, Christoph ^a   Pabinger, Ingrid ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; THROMBIN;

ADULT; AGE; AGED; ARTICLE; BRACHIAL VEIN THROMBOSIS; BRAIN CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER LOCALIZATION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURGERY; CEREBRAL SINUS THROMBOSIS; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GENDER; HEMOSTASIS; HUMAN; INFERIOR CAVA VEIN THROMBOSIS; INTESTINE CANCER; JUGULAR VEIN THROMBOSIS; KIDNEY CANCER; LEG THROMBOSIS; LUNG CANCER; LUNG EMBOLISM; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; OBSERVATIONAL STUDY; PANCREAS CANCER; POPULATION RESEARCH; PORTAL VEIN THROMBOSIS; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; RISK ASSESSMENT; STOMACH CANCER; SURGICAL TECHNIQUE; THROMBIN TIME; UPPER GASTROINTESTINAL TRACT; VENOUS THROMBOEMBOLISM;

FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; THROMBIN; VENOUS THROMBOEMBOLISM;

EID: 79957517025     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.32.8294     Document Type: Article

References (31)

1. Rickles FR, Patierno S, Fernandez PM: Tissue factor, thrombin, and cancer. Chest 124:58S-68S, 2003 (Pubitemid 37128437)
2. Falanga A, Panova-Noeva M, Russo L: Procoagulant mechanisms in tumour cells. Best Pract Res Clin Haematol 22:49-60, 2009
3. Wun T, White RH: Venous thromboembolism (VTE) in patients with cancer: Epidemiology and risk factors. Cancer Invest 27:63-74, 2009 (suppl 1)
4. Lyman GH, Khorana AA: Cancer, clots and consensus: New understanding of an old problem. J Clin Oncol 27:4821-4826, 2009
5. Bick RL: Cancer-associated thrombosis. N Engl J Med 349:109-111, 2003 (Pubitemid 36818779)
6. Lip GY, Chin BS, Blann AD: Cancer and the prothrombotic state. Lancet Oncol 3:27-34, 2002 (Pubitemid 34121143)
7. Baglin T: The measurement and application of thrombin generation. Br J Haematol 130:653-661, 2005 (Pubitemid 43906639)
8. Pabinger I, Ay C: Biomarkers and venous thromboembolism. Arterioscler Thromb Vasc Biol 29:332-336, 2009
9. Hemker HC, Al Dieri R, De Smedt E, et al: Thrombin generation, a function test of the haemostaticthrombotic system. Thromb Haemost 96:553-561, 2006 (Pubitemid 44782533)
10. van Veen JJ, Gatt A, Makris M: Thrombin generation testing in routine clinical practice: Are we there yet? Br J Haematol 142:889-903, 2008
11. Lutsey PL, Folsom AR, Heckbert SR, et al: Peak thrombin generation and subsequent venous thromboembolism: The Longitudinal Investigation of Thromboembolism Etiology (LITE) study. J Thromb Haemost 7:1639-1648, 2009
12. van Hylckama Vlieg A, Christiansen SC, Luddington R, et al: Elevated endogenous thrombin potential is associated with an increased risk of a first deep venous thrombosis but not with the risk of recurrence. Br J Haematol 138:769-774, 2007 (Pubitemid 47313221)
13. Hron G, Kollars M, Binder BR, et al: Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation. JAMA 296:397-402, 2006 (Pubitemid 44127523)
14. Tripodi A, Legnani C, Chantarangkul V, et al: High thrombin generation measured in the presence of thrombomodulin is associated with an increased risk of recurrent venous thromboembolism. J Thromb Haemost 6:1327-1333, 2008 (Pubitemid 352016312)
15. Eichinger S, Hron G, Kollars M, et al: Prediction of recurrent venous thromboembolism by endogenous thrombin potential and D-dimer. Clin Chem 54:2042-2048, 2008 (Pubitemid 352774038)
16. Besser M, Baglin C, Luddington R, et al: High rate of unprovoked recurrent venous thrombosis is associated with high thrombin-generating potential in a prospective cohort study. J Thromb Haemost 6:1720-1725, 2008
17. Ay C, Simanek R, Vormittag R, et al: High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: Results from the Vienna Cancer and Thrombosis Study (CATS). Blood 112:2703-2708, 2008
18. Ay C, Vormittag R, Dunkler D, et al: D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: Results from the Vienna Cancer and Thrombosis Study. J Clin Oncol 27:4124-4129, 2009
19. Vormittag R, Simanek R, Ay C, et al: High factor VIII levels independently predict venous thromboembolism in cancer patients: The cancer and thrombosis study. Arterioscler Thromb Vasc Biol 29:2176-2181, 2009
20. Ay L, Kopp HP, Brix JM, et al: Thrombin generation in morbid obesity: Significant reduction after weight loss. J Thromb Haemost 8:759-765, 2010
21. Lyman GH, Khorana AA, Falanga A, et al: American Society of Clinical Oncology guideline: Recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 25:5490-5505, 2007 (Pubitemid 350232226)
22. Geerts WH, Bergqvist D, Pineo GF, et al: Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (ed 8). Chest 133:381S-453S, 2008 (Pubitemid 351894916)
23. Agnelli G, Gussoni G, Bianchini C, et al: Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: A randomised, placebo-controlled, double-blind study. Lancet Oncol 10:943-949, 2009
24. Riess H, Pelzer U, Deutschinoff G, et al: A prospective, randomized trial of chemotherapy with or without the low molecular weight heparin (LMWH) enoxaparin in patients (pts) with advanced pancreatic cancer (APC): Results of the CONKO 004 trial. J Clin Oncol 27:203s, 2009 (suppl; abstr LBA4506)
25. Maraveyas A, Waters J, Roy R, et al: Gemcitabine with or without prophylactic weight-adjusted dalteparin (WAD) in patients with advanced or metastatic pancreatic cancer (APC): A multicentre, randomized phase IIB trial (the UK FRAGEM study). Thromb Res 125:S161-5 (OC-02), 2010 (suppl 2)
26. Khorana AA, Kuderer NM, Culakova E, et al: Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 111:4902-4907, 2008
27. Ay C, Dunkler D, Marosi C, et al: Prediction of venous thromboembolism in cancer patients. Blood 116:5377-5382, 2010
28. Goldenberg N, Kahn SR, Solymoss S: Markers of coagulation and angiogenesis in cancer-associated venous thromboembolism. J Clin Oncol 21:4194-4199, 2003 (Pubitemid 46606188)
29. Edwards RL, Rickles FR, Moritz TE, et al: Abnormalities of blood coagulation tests in patients with cancer. Am J Clin Pathol 88:596-602, 1987 (Pubitemid 18014618)
30. Sallah S, Husain A, Sigounas V, et al: Plasma coagulation markers in patients with solid tumors and venous thromboembolic disease receiving oral anticoagulation therapy. Clin Cancer Res 10:7238-7243, 2004 (Pubitemid 39487710)
31. Cosmi B, Legnani C, Cini M, et al: The role of D-dimer and residual venous obstruction in recurrence of venous thromboembolism after anticoagulation withdrawal in cancer patients. Haematologica 90:713-715, 2005 (Pubitemid 40780904)